Related references
Note: Only part of the references are listed.
Article
Multidisciplinary Sciences
Elisabetta Cameroni et al.
Summary: The Omicron variant of SARS-CoV-2 has raised concerns due to its 37 amino acid substitutions in the spike protein, particularly in the receptor-binding domain (RBD), leading to increased binding affinity with human ACE2. Neutralizing activity against Omicron was greatly reduced in convalescent and vaccinated individuals compared to the ancestral virus, but this decrease was less significant after a third vaccine dose. Broadly neutralizing monoclonal antibodies recognizing conserved RBD epitopes may be crucial in combating the Omicron variant and future zoonotic transmissions.
Article
Multidisciplinary Sciences
Sandile Cele et al.
Summary: The study found that the Omicron variant has reduced neutralizing effectiveness in individuals vaccinated with Pfizer BNT162b2, but those who had previously been infected with SARS-CoV-2 showed better neutralization against Omicron.
Letter
Medicine, General & Internal
Fabian Schmidt et al.
Summary: Neutralization assays showed much lower omicron neutralization compared to Wuhan-hu-1 after two doses of mRNA vaccine, but individuals who received a booster vaccine or were vaccinated after recovering from Covid-19 exhibited high levels of omicron neutralization.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Pharmacology & Pharmacy
Saborni Chakraborty et al.
Summary: The ongoing COVID-19 pandemic has accelerated the development of investigational vaccines, with collaborative efforts leading to several SARS-CoV-2 vaccine candidates moving into Phase III trials in a short period of time. Current research focuses on vaccine platforms and targeted antigens to enhance the breadth and durability of vaccine responses against SARS-CoV-2.
ADVANCED DRUG DELIVERY REVIEWS
(2021)
Article
Biochemistry & Molecular Biology
Daming Zhou et al.
Summary: The race to develop vaccines against SARS-CoV-2 variants, such as B.1.1.7, B.1.351, and P.1, is ongoing as these variants have mutations in the spike protein, potentially leading to immune escape. A structure-function analysis of B.1.351 revealed tighter ACE2 binding and widespread evasion from monoclonal antibody neutralization, particularly driven by the E484K mutation.
Editorial Material
Medicine, General & Internal
Salim S. Abdool Karim et al.
Article
Biochemistry & Molecular Biology
Shuo Feng et al.
Summary: Defined levels of SARS-CoV-2-specific binding and neutralizing antibodies elicited by the COVID-19 vaccine were identified as correlates of protection against symptomatic infection. Higher levels of immune markers were correlated with a reduced risk of symptomatic infection. The data can be used to extrapolate efficacy estimates to new populations.
Article
Multidisciplinary Sciences
Pengfei Wang et al.
Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.
Article
Multidisciplinary Sciences
Matthew McCallum et al.
Summary: The transmission of SARS-CoV-2 leads to the emergence of variants, such as the B.1.617.2 (Delta) variant, which dampens the in vitro potency of vaccine-elicited serum neutralizing antibodies. Mutations in the B.1.617.1 (Kappa) and Delta spike glycoproteins alter key antigenic sites, affecting the recognition by monoclonal antibodies. The angiotensin-converting enzyme 2 binding affinities of Kappa and Delta are comparable to the Wuhan-Hu-1 isolate, while Delta+ exhibits significantly reduced affinity.
Article
Cell Biology
Chloe Rees-Spear et al.
Summary: The study found that emerging variants of the coronavirus may lead to reduced neutralization by antibodies induced by vaccines or previous infection, but some samples still retain effectiveness. This highlights the importance of real-time monitoring of emerging mutations and their impact on vaccine efficacy.
News Item
Medicine, General & Internal
Ingrid Torjesen
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Medicine, General & Internal
Ai-ris Y. Collier et al.
Summary: This study assessed the immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women, as well as the responses against emerging SARS-CoV-2 variants. The results showed that pregnant, lactating, and nonpregnant women developed antibody and T-cell responses following vaccination, with antibodies transferred to infant cord blood and breast milk. While antibody titers against the B.1.1.7 and B.1.351 variants were reduced, T-cell responses remained against the viral variants.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Multidisciplinary Sciences
Prasanna Jagannathan et al.
Summary: A randomized, single-blind, placebo-controlled trial on 120 outpatients with mild to moderate COVID-19 showed that a single subcutaneous dose of Peginterferon Lambda-1a (Lambda) did not shorten the duration of SARS-CoV-2 viral shedding or improve symptoms. The treatment was well tolerated but did not have a significant impact on the outcomes of the patients.
NATURE COMMUNICATIONS
(2021)
Article
Pediatrics
Jose Villar et al.
Summary: This study evaluated the risks associated with COVID-19 in pregnancy on maternal and neonatal outcomes compared with pregnant individuals without COVID-19, finding that pregnant individuals with COVID-19 were at higher risk for various complications such as preeclampsia, severe infections, and preterm birth. The findings emphasize the importance for pregnant individuals and clinicians to strictly implement recommended COVID-19 preventive measures.
Article
Infectious Diseases
Mehrdad Mohammadi et al.
Summary: This review discusses the impact of spike mutated variants of SARS-CoV2 (Alpha, Beta, Gamma, Delta, and Lambda) on the efficacy of subunit recombinant vaccines. To date, there have been reports of low or no significant impact on vaccine efficacy against Alpha and Delta variants. However, impacts on vaccine efficacy for Beta, Gamma, Delta, and Lambda variants may be even greater, requiring more comprehensive analyses to assess the real impact on vaccine efficacy brought about by SARS-CoV-2 variants.
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Multidisciplinary Sciences
Prabhu S. Arunachalam et al.
Summary: The study found that vaccination with the Pfizer-BioNTech mRNA vaccine can induce immune responses against neutralizing antibodies and CD4, CD8 T cells of SARS-CoV-2. Booster vaccines can significantly enhance innate immune responses, and different innate pathways associated with CD8 T cells and neutralizing antibodies have been identified.
Article
Biochemistry & Molecular Biology
Erin M. Bange et al.
Summary: In patients with cancer and COVID-19, those with hematologic cancer show impaired immune responses compared to solid cancer patients. CD8 T cells play a crucial role in survival, even in the presence of limited humoral responses. The presence of SARS-CoV-2-specific T cell responses in hematologic cancer patients suggests a potential therapeutic target.
Article
Multidisciplinary Sciences
Amarendra Pegu et al.
Summary: The study assessed the impact of SARS-CoV-2 variants on antibody responses induced by the mRNA vaccine over 7 months, showing that most individuals maintained binding and functional antibodies against variants, with B.1.351 having the lowest antibody recognition.
Article
Multidisciplinary Sciences
Kathryn M. Hastie et al.
Summary: Antibody-based therapeutics and vaccines are crucial in combating COVID-19, especially with mutations and transmission of SARS-CoV-2. An international consortium identified multiple RBD-directed antibody communities, providing a framework for selecting treatment cocktails.
Article
Immunology
Vamsee Mallajosyula et al.
Summary: The study suggests that CD8(+) T cells with conserved specificities are more abundant in COVID-19 patients with mild disease, indicating a potential protective role.
SCIENCE IMMUNOLOGY
(2021)
Article
Immunology
Saborni Chakraborty et al.
Summary: COVID-19 is often characterized by a hyperinflammatory syndrome, and disease severity is associated with specific antibody structures that enhance inflammatory responses.
Article
Multidisciplinary Sciences
Jerome Hadjadj et al.
Article
Immunology
Emma M. Bentley et al.
Article
Multidisciplinary Sciences
Daniel G. Gibson et al.
Article
Immunology
Edward Wright et al.
